Allogeneic transplantation for lymphoma: Long-term outcome

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose of Review: In the last 20 years, allogeneic stem cell transplantation (alloSCT) has been increasingly applied in lymphoma patients, due to the shift towards reduced intensity and nonmyeloablative conditioning. This review reports on the most significant long-term results of allografted lymphoma patients coming from both prospective studies and retrospective analyses. Recent Findings: AlloSCT can cure 40-60% of aggressive B-cell lymphomas, but an unfavourable outcome has been observed in case of chemorefractory and active disease at the time of allografting. Indolent lymphoma displays the best outcome, and reduced-intensity alloSCT should be always considered in patients relapsing after an autologous SCT and in cases of chemorefractory disease. Most recent findings in Hodgkin's and T-cell lymphoma are also encouraging. Summary: Although the nonrelapse mortality has been reduced and survival curves show a plateau, the analysis of the long-term outcome reveals that a significant proportion of patients still experiences disease relapse and delayed morbidity and mortality. At the best of our knowledge, the process of decision-making should be based on lymphoma subtype, chemosensitivity, disease status and patient comorbidities at the time of allografting. To answer some of the still open questions, physicians should try to improve the enrolment of patients in multicentre prospective clinical trials.

Original languageEnglish
Pages (from-to)522-530
Number of pages9
JournalCurrent Opinion in Hematology
Volume17
Issue number6
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Homologous Transplantation
Lymphoma
Stem Cell Transplantation
Mortality
T-Cell Lymphoma
B-Cell Lymphoma
Hodgkin Disease
Comorbidity
Decision Making
Clinical Trials
Prospective Studies
Morbidity
Physicians
Recurrence
Survival

Keywords

  • allogeneic
  • long-term
  • lymphoma
  • reduced-intensity

ASJC Scopus subject areas

  • Hematology

Cite this

Allogeneic transplantation for lymphoma : Long-term outcome. / Corradini, Paolo; Farina, Lucia.

In: Current Opinion in Hematology, Vol. 17, No. 6, 11.2010, p. 522-530.

Research output: Contribution to journalArticle

@article{594b974b1f3f4ad1a5406d6a5f1b1636,
title = "Allogeneic transplantation for lymphoma: Long-term outcome",
abstract = "Purpose of Review: In the last 20 years, allogeneic stem cell transplantation (alloSCT) has been increasingly applied in lymphoma patients, due to the shift towards reduced intensity and nonmyeloablative conditioning. This review reports on the most significant long-term results of allografted lymphoma patients coming from both prospective studies and retrospective analyses. Recent Findings: AlloSCT can cure 40-60{\%} of aggressive B-cell lymphomas, but an unfavourable outcome has been observed in case of chemorefractory and active disease at the time of allografting. Indolent lymphoma displays the best outcome, and reduced-intensity alloSCT should be always considered in patients relapsing after an autologous SCT and in cases of chemorefractory disease. Most recent findings in Hodgkin's and T-cell lymphoma are also encouraging. Summary: Although the nonrelapse mortality has been reduced and survival curves show a plateau, the analysis of the long-term outcome reveals that a significant proportion of patients still experiences disease relapse and delayed morbidity and mortality. At the best of our knowledge, the process of decision-making should be based on lymphoma subtype, chemosensitivity, disease status and patient comorbidities at the time of allografting. To answer some of the still open questions, physicians should try to improve the enrolment of patients in multicentre prospective clinical trials.",
keywords = "allogeneic, long-term, lymphoma, reduced-intensity",
author = "Paolo Corradini and Lucia Farina",
year = "2010",
month = "11",
doi = "10.1097/MOH.0b013e32833e5b41",
language = "English",
volume = "17",
pages = "522--530",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Allogeneic transplantation for lymphoma

T2 - Long-term outcome

AU - Corradini, Paolo

AU - Farina, Lucia

PY - 2010/11

Y1 - 2010/11

N2 - Purpose of Review: In the last 20 years, allogeneic stem cell transplantation (alloSCT) has been increasingly applied in lymphoma patients, due to the shift towards reduced intensity and nonmyeloablative conditioning. This review reports on the most significant long-term results of allografted lymphoma patients coming from both prospective studies and retrospective analyses. Recent Findings: AlloSCT can cure 40-60% of aggressive B-cell lymphomas, but an unfavourable outcome has been observed in case of chemorefractory and active disease at the time of allografting. Indolent lymphoma displays the best outcome, and reduced-intensity alloSCT should be always considered in patients relapsing after an autologous SCT and in cases of chemorefractory disease. Most recent findings in Hodgkin's and T-cell lymphoma are also encouraging. Summary: Although the nonrelapse mortality has been reduced and survival curves show a plateau, the analysis of the long-term outcome reveals that a significant proportion of patients still experiences disease relapse and delayed morbidity and mortality. At the best of our knowledge, the process of decision-making should be based on lymphoma subtype, chemosensitivity, disease status and patient comorbidities at the time of allografting. To answer some of the still open questions, physicians should try to improve the enrolment of patients in multicentre prospective clinical trials.

AB - Purpose of Review: In the last 20 years, allogeneic stem cell transplantation (alloSCT) has been increasingly applied in lymphoma patients, due to the shift towards reduced intensity and nonmyeloablative conditioning. This review reports on the most significant long-term results of allografted lymphoma patients coming from both prospective studies and retrospective analyses. Recent Findings: AlloSCT can cure 40-60% of aggressive B-cell lymphomas, but an unfavourable outcome has been observed in case of chemorefractory and active disease at the time of allografting. Indolent lymphoma displays the best outcome, and reduced-intensity alloSCT should be always considered in patients relapsing after an autologous SCT and in cases of chemorefractory disease. Most recent findings in Hodgkin's and T-cell lymphoma are also encouraging. Summary: Although the nonrelapse mortality has been reduced and survival curves show a plateau, the analysis of the long-term outcome reveals that a significant proportion of patients still experiences disease relapse and delayed morbidity and mortality. At the best of our knowledge, the process of decision-making should be based on lymphoma subtype, chemosensitivity, disease status and patient comorbidities at the time of allografting. To answer some of the still open questions, physicians should try to improve the enrolment of patients in multicentre prospective clinical trials.

KW - allogeneic

KW - long-term

KW - lymphoma

KW - reduced-intensity

UR - http://www.scopus.com/inward/record.url?scp=77958538544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958538544&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e32833e5b41

DO - 10.1097/MOH.0b013e32833e5b41

M3 - Article

C2 - 20717024

AN - SCOPUS:77958538544

VL - 17

SP - 522

EP - 530

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 6

ER -